Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Cellular senescence
Research brief

Narrative review: immunometabolic mechanisms of coronary microvascular dysfunction in chronic coronary syndromes

This narrative review proposes a systems-level framework in which coronary microvascular dysfunction in chronic coronary syndromes is viewed as an immunometabolic vascular network disorder, with reduced coronary flow reserve as an integrative functional endpoint. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The review states that coronary microvascular dysfunction is a major determinant of myocardial ischemia, heart failure progression and adverse cardiovascular outcomes, even without obstructive coronary artery disease. [1]

  2. According to the review, mitochondrial stress including NAD decline and redox injury promote endothelial senescence and increase susceptibility to regulated cell death. [1]

  3. The authors propose a framework in which reduced coronary flow reserve is the integrative functional endpoint and a robust predictor of major cardiovascular events. [1]

The source at a glance

Study type / format
Narrative review (abstract only)
Population / context
People with chronic coronary syndromes and coronary microvascular dysfunction, as discussed in a narrative review.
Summary based on
Study abstract
Original publication
June 23, 2026

Coronary microvascular dysfunction beyond epicardial stenosis

The review describes chronic coronary syndromes as complex immunometabolic vascular disorders. Coronary microvascular dysfunction is presented as a heterogeneous condition with functional and structural endotypes and as a major determinant of myocardial ischemia, heart failure progression and adverse cardiovascular outcomes, even without obstructive coronary artery disease.

Supporting source [1]

Proposed network of mitochondrial stress and endothelial senescence

According to the review, metabolic shifts toward glycolysis, mitochondrial dysfunction, redox imbalance and dysregulated lipid metabolism sustain inflammatory activation in the coronary microenvironment. Convergent mitochondrial stress, including NAD decline, and redox injury are said to promote endothelial senescence and increase susceptibility to regulated cell death, limiting vasodilatory reserve and predisposing to microvascular rarefaction. Pyroptosis and ferroptosis-like lipid peroxidation are described as further worsening endothelial barrier disruption.

Supporting source [1]

Reduced coronary flow reserve as proposed integrative endpoint

The authors propose a systems-level framework in which coronary microvascular dysfunction is conceptualized as an immunometabolic vascular network disorder. Reduced coronary flow reserve, often termed myocardial flow reserve in PET studies, is presented as the integrative functional endpoint of these interacting molecular perturbations and as a robust predictor of major cardiovascular events.

Supporting source [1]

How to interpret this

This is a narrative review; the abstract reports no study design, sample, follow-up or effect sizes, and the full text was not reviewed. The systems-level framework is proposed, not validated. Associations described are not established causes, and the molecular mechanisms are not shown to extend human lifespan.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    even in the absence of obstructive coronary
  2. Finding 2 ↑

    promote endothelial senescence and increase susceptibility to
  3. Finding 3 ↑

    a robust predictor of major cardiovascular events

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…